Stoke Therapeutics, Inc.STOKNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +707.07% | +3661.12% | +186.01% | +117.25% | -93.80% |
| Gross Profit Growth | +1324.95% | +5010.18% | +271.32% | +97.04% | -98.47% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +26.85% | +25.12% | +4.64% | +4.03% | +2.38% |
| Weighted Average Shares Diluted Growth | +26.85% | +28.44% | +4.64% | +4.03% | +2.38% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +993.75% | +5409.09% | +431.80% | +1468.31% | +1029.29% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +18.92% | +98.31% | +24.94% | +22.82% | +54.09% |
| Book Value per Share Growth | +13.15% | +99.37% | +31.88% | +27.60% | +50.31% |
| Debt Growth | +12.61% | +6.24% | +0.83% | +26.54% | -100.00% |
| R&D Expense Growth | +10.73% | +49.86% | +25.58% | +67.77% | +76.28% |
| SG&A Expenses Growth | +28.20% | +51.53% | +22.34% | +21.97% | +59.58% |